IMMUNOCORE HLDGS ADS/1 Cash Flow Reinvestment Rate
IMMUNOCORE HLDGS ADS/1 cash flow reinvestment rate. IMMUNOCORE HLDGS ADS/1 (6YG) has a Cash Flow Reinvestment Rate of 0.05x as of June 2026, reinvesting €786.00K (capex €786.00K ) from operating cash flow of €15.93 Million. Explore debt repayment capacity of IMMUNOCORE HLDGS ADS/1 to assess how comfortably operating cash covers total debt obligations.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Cash Flow Reinvestment Rate of IMMUNOCORE HLDGS ADS/1 (2023–2024)
Cash flow reinvestment rate of IMMUNOCORE HLDGS ADS/1 from 2023 to 2024. Historical reinvestment intensity for IMMUNOCORE HLDGS ADS/1 across 2 annual periods. Explore IMMUNOCORE HLDGS ADS/1 (6YG) reinvestment ratio to see what proportion of operating cash flow is directed to capital expenditures.
IMMUNOCORE HLDGS ADS/1 Cash Flow Reinvestment Rate by Year (2023–2024)
IMMUNOCORE HLDGS ADS/1 cash flow reinvestment rate by year from 2023 to 2024. Year-by-year capital reinvestment analysis for IMMUNOCORE HLDGS ADS/1. For the full cash flow conversion analysis, see 6YG operating cash flow.
| Year | Reinvestment Rate | Total Reinvested (EUR) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2024 | 13.63x | €355.17 Million | €26.06 Million | €5.17 Million | ▲ +638.6% |
| 2023 | 1.85x | €5.42 Million | €2.94 Million | €5.42 Million | — |